CDMRP: Duchenne Muscular Dystrophy Research Program (DMDRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Duchenne Muscular Dystrophy Research Program (DMDRP), managed by the Congressionally Directed Medical Research Programs (CDMRP), will fund high-impact research to improve function and quality of life for individuals with Duchenne muscular dystrophy (DMD). This is a pre-announcement, meaning application deadlines are not yet specified. Founders and investigators should begin preparing now ahead of the official release on Grants.gov, where deadlines will be published.

How much funding would I receive?

Two award mechanisms are anticipated:

Idea Development Award

  • Maximum funding: $500,000 in total costs

  • Period of performance: 2 years

Clinical/Translational Research Award

Funding Level 1

  • Single PI: $910,000 in total costs

  • Partnering PI Option: $1 million in total costs

  • Period of performance: 3 years

Funding Level 2

  • Single PI: $1.75M in total costs

  • Partnering PI Option: $1.9M in total costs

  • Period of performance: 4 years

Total costs include direct and indirect costs.

What could I use the funding for?

Idea Development Award

  • High-risk/high-reward research advancing understanding of DMD

  • Development of macromolecular and cellular therapies targeting primary pathology

  • Research must include preliminary data

  • Cannot fund clinical trials or clinical trial aims

Clinical/Translational Research Award

  • Translational research with near-term clinical impact

  • Preclinical work supporting IND-enabling studies

  • Clinical research including:

    • Real-world data or post-market studies

    • Combination or sequential therapy studies

    • Long-term safety and efficacy studies

    • Studies to improve care and quality of life

    • Clinical trial tools and outcome measures

    • Natural history studies for trial readiness

  • Can include clinical trials, pilot trials, and readiness studies

  • Must include preliminary data

Are there any additional benefits I would receive?

  • Access to CDMRP-managed funding programs within the Defense Health Agency Research and Development ecosystem

  • Optional Partnering PI structure for Clinical/Translational Research Awards to support collaboration between investigators

What is the timeline to apply and when would I receive funding?

  • This is a pre-announcement only

  • Pre-application and full application deadlines are not specified

  • Deadlines will be released with the official funding opportunity announcements on Grants.gov

  • A pre-application submission through eBRAP is required prior to full application submission

Where does this funding come from?

  • FY26 Defense Appropriations Act

  • Managed by the Congressionally Directed Medical Research Programs (CDMRP)

  • Under the Defense Health Agency Research and Development – Medical Research and Development Command (DHA R&D-MRDC)

Who is eligible to apply?

Idea Development Award

  • Established independent investigators

  • Early-stage investigators:

    • Within 10 years of first faculty appointment

    • Must not have previously received this award

  • Transitioning investigators entering DMD from another field

  • Must:

    • Be pursuing an active line of DMD research

    • Commit at least 10% effort annually

Clinical/Translational Research Award

  • Independent investigators at all academic levels

  • Optional Partnering PI must be:

    • Early-career (within 10 years), or

    • Established investigator from another field entering DMD

What companies and projects are likely to win?

  • Projects focused on safe and effective macromolecular and cellular therapies addressing the primary pathology of DMD

  • Research with clinical relevance and translational potential

  • Studies that demonstrate impact across the lifespan, including:

    • Infants

    • Toddlers

    • Non-ambulatory individuals

  • Applications supported by strong preliminary data

  • High-risk/high-reward ideas (Idea Development Award) or near-term clinical impact (Clinical/Translational Award)

Are there any restrictions I should know about?

  • Idea Development Award:

    • Cannot fund clinical trials or clinical trial aims

  • All applications:

    • Must include preliminary data

    • Must align with specified focus areas

  • Pre-application submission via eBRAP is required

  • Applications must conform to final FOA requirements once released

How long will it take me to prepare an application?

  • Not specified in the pre-announcement

  • However, preparation should begin now given:

    • Required preliminary data

    • Mandatory pre-application step

    • Competitive, high-impact nature of the program

How can BW&CO help?

  • Evaluate fit across Idea Development vs. Clinical/Translational tracks

  • Shape your research into a CDMRP-aligned, reviewer-ready narrative

  • Support Partnering PI strategy and positioning

  • Develop compliant pre-applications and full submissions

  • Maximize competitiveness for high-risk/high-reward and translational proposals

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Previous
Previous

CDMRP: Parkinson’s Research Program (PRP)

Next
Next

CDMRP: Pharmacotherapies for Alcohol and Substance Use Disorder Alliance (PASA)